nivolumab,trastuzumab,docetaxel,pyrotinib
bms
['melanoma', 'opdivo', 'nivo', 'phila', 'nivolumab', 'check,mate,76k', 'bmsnews', 'bms']
. presents data from checkmate -76k showing opdivo (nivolumab) reduced the risk of recurrence or death by 58% versus placebo in patients with completely resected stage iib or iic melanoma. #biotech #philadelphia
Part of the @big4bio life science hub coverage network. Subscribe to the Big4Bio:Philly daily newsletter for FREE: https://t.co/sw1AAeEcLu